Alnylam Pharmaceuticals receives ‘See of Allowance’ from USPTO Alnylam Pharmaceuticals, Inc. 10/916,185), which covers certain altered siRNAs of any duration directed to any target chemically, including siRNAs with sterol conjugates for in vivo delivery. The brand new patent is founded on the ground-breaking study by Alnylam scientists on systemic delivery of RNAi therapeutics as documented in Soutschek et al. ). This landmark paper was the first to present RNAi-mediated gene silencing in mammals with systemic delivery of chemically altered RNAi therapeutics in vivo.Under the ACA, Medicaid could be expanded to Florida occupants with incomes up to 138 % of the federal poverty level, or $27,310 for a family of three. Up to now, Florida legislators have declined to act . In other Medicaid news – Kaiser Health Information: Capsules: Moving Kids From CHIP To Exchange Plans Would Boost Costs: Study Price sharing would increase and the number of child-specific solutions covered would decline if millions of low-income children right now enrolled in the Children's MEDICAL HEALTH INSURANCE Plan were forced to receive coverage through medical regulation's insurance exchanges, according to a report released Tuesday . Related StoriesSurgical startup seeks financing to build virtual reality training libraryApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiReducing medical center readmissions through Transitional Treatment: an interview with Rani KhetarpalModern Healthcare: Uninsured Rate Drops Faster In Says That Expanded Medicaid Americans lacking insurance coverage are becoming more concentrated in says that have opted not to expand Medicaid, based on the latest study data from the Urban Institute's Health Policy Center.